In last trading session, Castle Biosciences Inc (NASDAQ:CSTL) saw 0.4 million shares changing hands with its beta currently measuring 0.95. Company’s recent per share price level of $33.29 trading at -$0.02 or -0.06% at ring of the bell on the day assigns it a market valuation of $932.36M. That closing price of CSTL’s stock is at a discount of -7.66% from its 52-week high price of $35.84 and is indicating a premium of 51.34% from its 52-week low price of $16.20. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.54 million shares which gives us an average trading volume of 394.57K if we extend that period to 3-months.

For Castle Biosciences Inc (CSTL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.11. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.21 in the current quarter.

Castle Biosciences Inc (NASDAQ:CSTL) trade information

Upright in the red during last session for losing -0.06%, in the last five days CSTL remained trading in the green while hitting it’s week-highest on Tuesday, 11/05/24 when the stock touched $33.29 price level, adding 7.11% to its value on the day. Castle Biosciences Inc’s shares saw a change of 54.26% in year-to-date performance and have moved 0.42% in past 5-day. Castle Biosciences Inc (NASDAQ:CSTL) showed a performance of 17.63% in past 30-days. Number of shares sold short was 1.75 million shares which calculate 4.39 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 40.5 to the stock, which implies a rise of 17.8% to its current value. Analysts have been projecting 36 as a low price target for the stock while placing it at a high target of 45. It follows that stock’s current price would drop -8.14% in reaching the projected high whereas dropping to the targeted low would mean a loss of -8.14% for stock’s current value.

Castle Biosciences Inc (CSTL) estimates and forecasts

Statistics highlight that Castle Biosciences Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 37.33% of value to its shares in past 6 months, showing an annual growth rate of 96.26% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 46.10% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 75.4M for the same. And 7 analysts are in estimates of company making revenue of 59.59M in the next quarter. Company posted 66.12M and 72.97M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -28.57% during past 5 years.

Castle Biosciences Inc (NASDAQ:CSTL)’s Major holders

Insiders are in possession of 3.25% of company’s total shares while institution are holding 93.98 percent of that, with stock having share float percentage of 97.14%. Investors also watch the number of corporate investors in a company very closely, which is 93.98% institutions for Castle Biosciences Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CSTL for having 3.04 million shares of worth $66.29 million. And as of 2024-06-30, it was holding 11.0787 of the company’s outstanding shares.

The second largest institutional holder is WASATCH ADVISORS LP, which was holding about 2.33 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.4698 of outstanding shares, having a total worth of $50.68 million.